Emergent BioSolutionsRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Emergent BioSolutions (EBS) reported revenue of $234.00M in Q2 2026, with Product its largest revenue segment at 97%.
Q3 2016-Q2 2026
Q3 2016-Q2 2026
Emergent BioSolutionsUS biodefense contractor. Anthrax (BioThrax, CYFENDUS) and smallpox stockpile products for BARDA and the Strategic National Stockpile.
Emergent BioSolutions (EBS) is a Drug Manufacturers - Specialty & Generic company. US biodefense contractor. Anthrax (BioThrax, CYFENDUS) and smallpox stockpile products for BARDA and the Strategic National Stockpile. It was founded in 1998, is headquartered in Gaithersburg, MD and employs about 1,600 people.
As of 2026-Q2, Emergent BioSolutions's revenue breaks down across Product (97%), Contracts and Grants (3%). See the revenue-by-segment chart for the full mix.
Track Emergent BioSolutions's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 19, 2026.
Sterling groups Emergent BioSolutions in the Vaccines sector, alongside GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), Moderna (MRNA) and BioNTech (BNTX).
If you are researching Emergent BioSolutions, also look at GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK). You can compare all of them side by side or browse the full Vaccines sector on Sterling.